• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Ecor1 Panacea Holdings Ii, Llc

    5/2/23 5:15:46 PM ET
    $PANA
    Blank Checks
    Finance
    Get the next $PANA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    EcoR1 Panacea Holdings II, LLC

    (Last) (First) (Middle)
    C/O PANACEA ACQUISITION CORP. II
    357 TEHAMA STREET, FLOOR 3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Panacea Acquisition Corp. II [ PANA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/28/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A ordinary shares 04/28/2023 D(1) 545,000 D (1) 0 D(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    EcoR1 Panacea Holdings II, LLC

    (Last) (First) (Middle)
    C/O PANACEA ACQUISITION CORP. II
    357 TEHAMA STREET, FLOOR 3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    EcoR1 Capital Fund, L.P.

    (Last) (First) (Middle)
    C/O PANACEA ACQUISITION CORP. II
    357 TEHAMA STREET, FLOOR 3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    EcoR1 Capital Fund Qualified, L.P.

    (Last) (First) (Middle)
    C/O PANACEA ACQUISITION CORP. II
    357 TEHAMA STREET, FLOOR 3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    EcoR1 Venture Opportunity Fund, LP

    (Last) (First) (Middle)
    C/O PANACEA ACQUISITION CORP. II
    357 TEHAMA STREET, FLOOR 3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    EcoR1 Capital, LLC

    (Last) (First) (Middle)
    C/O PANACEA ACQUISITION CORP. II
    357 TEHAMA STREET, FLOOR 3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Biotech Opportunity GP, LLC

    (Last) (First) (Middle)
    C/O PANACEA ACQUISITION CORP. II
    357 TEHAMA STREET, FLOOR 3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    NODELMAN OLEG

    (Last) (First) (Middle)
    C/O PANACEA ACQUISITION CORP. II
    357 TEHAMA STREET, FLOOR 3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    Explanation of Responses:
    1. On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023.
    2. The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.
    Remarks:
    Oleg Nodelman, the manager of each of the General Partners, serves on the board of directors of the Company. For the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons (other than Mr. Nodelman) may be deemed a director by deputization with respect to the Company on the basis of Mr. Nodelman's service on the Company's board of directors.
    EcoR1 Panacea Holdings II, LLC, By: /s/ Oleg Nodelman, Chief Executive Officer 05/02/2023
    EcoR1 Capital Fund, L.P., By: /s/ Oleg Nodelman, Manager of EcoR1 Capital, LLC, its general partner 05/02/2023
    EcoR1 Capital Fund Qualified, L.P., By: /s/ Oleg Nodelman, Manager of EcoR1 Capital, LLC, its general partner 05/02/2023
    EcoR1 Venture Opportunity Fund, L.P., By: /s/ Oleg Nodelman, Manager of Biotech Opportunity GP, LLC, its general partner 05/02/2023
    EcoR1 Capital, LLC, By: /s/ Oleg Nodelman, Manager 05/02/2023
    Biotech Opportunity GP, LLC, By: /s/ Oleg Nodelman, Manager 05/02/2023
    /s/ Oleg Nodelman 05/02/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PANA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PANA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ecor1 Panacea Holdings Ii, Llc

    4 - Panacea Acquisition Corp. II (0001828989) (Issuer)

    5/2/23 5:15:46 PM ET
    $PANA
    Blank Checks
    Finance

    SEC Form 4: EcoR1 Panacea Holdings II, LLC bought $5,450,000 worth of Class A ordinary shares (545,000 units at $10.00)

    4 - Panacea Acquisition Corp. II (0001828989) (Issuer)

    4/13/21 3:10:13 PM ET
    $PANA
    Blank Checks
    Finance

    SEC Form 3 filed by Llc Ii, Holdings Panacea Ecor1

    3 - Panacea Acquisition Corp. II (0001828989) (Issuer)

    4/6/21 8:37:38 PM ET
    $PANA
    Blank Checks
    Finance

    $PANA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company

    NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of its business combination with Panacea Acquisition Corp. (NYSE: PANA), a special purpose acquisition company (SPAC) sponsored by EcoR1 Capital. The resulting combined company will commence trading its shares on the New York Stock Exchange (NYSE) under the ticker symbol "NUVB" on February 11, 2021. The business combination was approved by Panacea's shareholders on February 9, 2021 and was previously approved by Nuvation Bio shareholders. Nuvation Bio's man

    2/10/21 4:05:00 PM ET
    $PANA
    Blank Checks
    Finance

    $PANA
    SEC Filings

    View All

    SEC Form 15-12G filed by Panacea Acquisition Corp. II

    15-12G - Panacea Acquisition Corp. II (0001828989) (Filer)

    4/28/23 1:18:26 PM ET
    $PANA
    Blank Checks
    Finance

    SEC Form 25-NSE filed by Panacea Acquisition Corp. II

    25-NSE - Panacea Acquisition Corp. II (0001828989) (Subject)

    4/18/23 4:29:11 PM ET
    $PANA
    Blank Checks
    Finance

    Panacea Acquisition Corp. II filed SEC Form 8-K: Other Events

    8-K - Panacea Acquisition Corp. II (0001828989) (Filer)

    4/10/23 4:11:09 PM ET
    $PANA
    Blank Checks
    Finance

    $PANA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Panacea Acquisition Corp. II (Amendment)

    SC 13G/A - Panacea Acquisition Corp. II (0001828989) (Subject)

    2/14/24 4:01:16 PM ET
    $PANA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Panacea Acquisition Corp. II (Amendment)

    SC 13G/A - Panacea Acquisition Corp. II (0001828989) (Subject)

    2/14/23 8:02:36 AM ET
    $PANA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Panacea Acquisition Corp. II (Amendment)

    SC 13G/A - Panacea Acquisition Corp. II (0001828989) (Subject)

    2/14/23 7:34:59 AM ET
    $PANA
    Blank Checks
    Finance